APP下载

Sipple综合征1例并文献复习

2019-05-28黄岸豪黎土轩谢建兴

中国医药导报 2019年11期

黄岸豪 黎土轩 谢建兴

[摘要] Sipple綜合征(MEN-2A)是一种可累及多种内分泌器官同时或相继出现病变的肿瘤综合征,作为一种罕见的呈家族性遗传的疾病,其发生与位于常染色体上的RET基因突变有关。RET基因通常表达在甲状腺C细胞、嗜铬细胞和甲状旁腺细胞上,故Sipple综合征在临床诊治过程中易漏诊为甲状腺髓样癌(MTC)、嗜铬细胞瘤(PHEO)、原发性甲状旁腺功能亢进症(PHPT)中一种或几种。广州中医药大学第一附属医院收治了1例具有嗜铬细胞瘤家族史的Sipple综合征患者,诊治过程中发现患者的多个内分泌器官(肾上腺、胰腺、甲状旁腺、甲状腺)及非内分泌器官(左侧股骨)发生病变,诊断上考虑为多发性内分泌肿瘤综合征(MEN)。而MEN包括由MEN-1基因突变引起的MEN-1及由RET基因突变引起的MEN-2,为明确诊断行MEN-1及RET基因检测,结果回报为RET基因突变导致的MEN-2A,即Sipple综合征。Sipple综合征的病变常累及肾上腺、甲状腺及甲状旁腺,故早期的诊断上是依赖对嗜铬细胞瘤、甲状腺髓样癌、甲状旁腺瘤等定位、定性的检查。RET基因是Sipple综合征诊断的金标准,手术是其主要的治疗措施。

[关键词] Sipple综合征;嗜铬细胞瘤;甲状腺髓样癌;甲状旁腺瘤;RET基因

[中图分类号] R736.6 [文献标识码] A [文章编号] 1673-7210(2019)04(b)-0154-04

A case of Sipple syndrome and literature review

HUANG Anhao1 LI Tuxuan2 XIE Jianxing3 MENG Lei3

1.Department of Urinary Surgery, Shenzhen Baoan District Hospital of Traditional Chinese Medicine, Guangdong Province, Shenzhen 518000, China; 2.Department of Urinary Surgery, the Second Affiliated Hospital of Guangdong Medical University, Guangdong Province, Zhanjiang 524000, China; 3.Department of Urinary Surgery, the First Affiliated Hospital of Guangdong University of Traditional Chinese Medicine, Guangdong Province, Guangzhou 510000, China

[Abstract] Sipple syndrome (MEN-2A) is a tumor syndrome that can affect multiple endocrine organs simultaneously or sequentially. As a rare familial inherited disease, it is associated with mutations in the RET gene located on the autosome. The RET gene is usually expressed on thyroid C cells, chromaffin cells and parathyroid cells, so Sipple syndrome is easily missed as one or more of Medullary carcinoma of the thyroid gland (MTC), pheochromocytoma (PHEO) and primary hyperparathyroidism (PHPT). One patient was admitted to the First Affiliated Hospital of Guangdong University of Traditional Chinese Medicine with a left adrenal mass, with the typical PHEO symptoms: palpitations and hyperhidrosis. During the diagnosis and treatment, multiple endocrine organs (adrenal, pancreas, parathyroid, thyroid) and non-endocrine organs (left femur) were found in the diagnosis, and MEN (multiple endocrine neoplasia) were diagnosed. MEN includes MEN-1 caused by mutation of MEN-1 gene and MEN-2 caused by mutation of RET gene.Aim to definite diagnosis, the patient took RET gene test and MEN-1 gene test after the surgery. The results were reported as MEN-2A caused by RET gene mutation. The lesions of Sipple syndrome often involve the adrenal, thyroid and parathyroid glands, so early diagnosis depends on the localization and qualitative diagnosis of pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenoma. RET gene is the gold standard for the diagnosis of Sipple syndrome,and surgery is the main treatment for it.

[Key words] Sipple syndrome; Pheochromocytoma; Medullary thyroid carcinoma; Parathyroid adenoma; RET gene

Sipple综合征(multiple endocrine neoplasia type Ⅱ,MEN-2A),即MEN-2A,一种可累及多种内分泌器官同时或相继出现病变的的呈家族性遗传的疾病,其发生与位于常染色体上的RET基因突变有关[1-6],主要表现为以甲状腺髓样癌(medullary thyroid carcinoma,MTC)为基础,伴/不伴嗜铬细胞瘤(pheochromocytoma,PHEO)、原发性甲状旁腺功能亢进症(primary hyperparathyroidism,PHPT)中一种或两种(①MTC,②MTC+PHEO,③MTC+PHPT,④MTC+PHEO+PHPT),同时因激素的异常分泌,常可累及非内分泌器官同时或相继出现病变,如肠、黏膜、角膜、骨骼等[7]。MEN-2型占所有肿瘤的0.02%~0.03%,患病率约为1/30000,男女比例约为1∶1,国外已报道500至1000多个家系,国内多为散在报道,其中Sipple综合征约占MEN-2的55%[8-10]。广州中医药大学第一附属医院诊治1例Sipple综合征患者,并经手术、病理及基因检测证实。本文就此病例进行回顾,对其诊治过程进行探讨。

1 病例资料

患者女,19岁,出现“大汗、全身乏力2年,加重伴心悸3个月”,1个月前查彩超发现左肾上腺肿物,遂于2017年10月10日至广州中医药大学第一附属医院住院治疗。查体:颈软,甲状腺Ⅲ度肿大,无满月脸、水牛背、皮肤紫纹、腹部肿块、向心性肥胖、四肢相对变细、皮肤菲薄、毳毛增加、颈后及锁骨上窝脂肪垫、腹部宽大紫紋等异常体征体貌。入院后患者血压波动在155~97/97~56 mmHg(1 mmHg=0.133 kPa),心率波动在94~147次/min。查游离三碘甲腺原氨酸(FT3)6.85 pmol/L(正常范围3.80~6.00 pmol/L);尿香草扁桃酸31.3 mg/24 h(正常范围0~12 mg/24 h);血钙2.63~2.83 mmol/L(正常范围2.11~2.52 mmol/L);碱性磷酸酶(ALP)121~140 U/L(正常范围35~100 U/L);糖化血红蛋白6.2%(正常范围4.0%~6.0%);喉、甲状腺MR平扫+增强:考虑为右侧甲状旁腺腺瘤;甲状腺彩超:甲状腺双侧叶结节并左侧叶结节钙化;肾、肾上腺MR平扫+增强:左侧肾上腺区占位性病变,考虑为嗜铬细胞瘤;全身长骨平片:左侧股骨远端低密度灶,考虑骨肿瘤或肿瘤样病变(软骨类肿瘤待排);全身骨扫描:左侧股骨远端局部骨代谢增高,符合局部骨肿瘤;24 h动态心电图:窦性心动过速,平均心室率110次/min;皮质醇、促肾上腺皮质激素(ACTH)、血管紧张素、醛固酮、肾素、尿17-羟皮质醇、尿17-酮类固醇、促甲状腺激素(TSH)、总甲状腺素(TT4)、总三碘甲状原氨酸(TT3)、游离甲状腺素(FT4)、抗甲状过氧化物酶抗体(anti-TPO)、抗甲状腺球蛋白抗体(anti-Tg)、血磷、血钾、颅脑MR、24 h动态血压、心脏彩超未见明显异常。患者具有嗜铬细胞瘤家族病史(其母及其舅在广州中医药大学第一附属医院确诊为PHEO)及甲状腺肿物家族病史(其姐在外院行甲状腺肿物切除,具体不详)。患者主要症状为大汗、心悸(入院时心率达147次/min),符合PHEO的“头痛、心悸、大汗”[11]三联征中的两条。综合患者症状、体质及检查结果,诊断考虑为左侧嗜铬细胞瘤,于2017年11月15日行腹腔镜下左肾上腺肿物切除术,术后病理为嗜铬细胞瘤:肿瘤细胞略嗜碱,包浆丰富,异型性不明显,排列呈巢团状,间质血窦丰富,未见瘤细胞浸润包膜:免疫组化示:CK(-),Vim(+),CD56(+),Syn(+),CgA(+),Ki-67(+<1%)(图1A)。同时因患者的多个内分泌器官出现功能异常(肾上腺、胰腺、甲状旁腺、甲状腺)及非内分泌器官(左侧股骨)发生病变,结合患者具有PHEO家族史、甲状腺肿物家族史,在经多学科联合诊治后,诊断上考虑为多发性内分泌肿瘤综合征,为明确诊断,采血送至金域检验中心行RET基因检测及MEN-1基因检测:MEN1基因未检测到突变;RET基因检测到杂合突变,突变命名为NM_020875.4: c1902C>(p.C634W),该突变为MEN2A致病性突变,即确诊为Sipple综合征;美国甲状腺协会(American thyroid association,ATA),根据侵袭性MTC发生风险将RET突变类型分为4个危险等级:ATA-D级(最高风险)、ATA-C级(较高风险)、ATA-B级(较低风险)、ATA-A级(最低风险);本样本检测到的突变属于ATA-C级(较高风险)。综合Sipple综合征的发病特点及甲状腺影像学检查结果来分析,考虑合并MTC、PHPT。于2018年3月29日行左侧甲状癌根治+右侧甲状旁腺瘤切除+左侧喉返神经探查术,术后病理为左甲状腺髓样癌:肿瘤组织浸润性生长,细胞轻度异型,胞浆丰富粉染,排列呈腺样、梁索样、器官样等;免疫组化:CK(+),Tg(-),CK19(-),TPO(-),CD56(+),Syn(+),CgA(+),MC(-)(图1B);右甲状腺下极后方甲状旁腺腺瘤;右甲状腺中下极非毒性结节性甲状腺肿,支持MTC、PHPT诊断。通过基因检测,患者已确诊为Sipple综合征,该疾病通常呈家系存在,建议其一级亲属行RET基因检测,以便为潜在患者提供相应的诊治或预防性诊治,但出于经济原因,患者一级亲属暂拒绝行RET基因检测。

2 讨论

Sipple综合征,一种累及多个内分泌器官及非内分泌器官的疾病,在临床诊治过程中很容易漏诊为MTC、PHPT或PHEO中一种或几种。这提示我们在对某种内分泌疾病进行诊治时,应检查有无合并其他病变(如其他内分泌器官病变),详细询问有无某种内分泌疾病的家族史。当患者存在明显的某种疾病的家族史时或诊断上考虑可能为遗传性疾病时,应建议其行相应的基因检测。仅PHEO而言,目前已发现约30%PHEO患者具有明显的家族遗传病史,且一部分致病基因已被明确:①VHL基因,突变可导致的VHL病[12-3];②MEN-1基因,突变可导致的MEN-1[14-15];③MEN-2基因,突变可导致的MEN-2[16];④SDHD、SDHB、SDHC基因,突变可导致的家族性PHEO-PGL综合征[17];⑤NF-1基因,突变可导致的神经纤维瘤病-1型[18]。Sipple综合征的发病机制虽未被完全明确,但约100%患者被发现其位于染色体10q11.2上的RET原癌基因发生突变[1],因而RET基因檢测是以Sipple综合征为代表的MNE-2的诊断金标准。RET基因突变主要会导致以下几种病变:参与神经脊在内的异常生长或分化,诱导细胞异常增生甚至形成肿瘤,突变的位点主要发生在第10外显子上的609、611、618、620和第11外显子的634编码子(为最常见的突变位点,占85%~87%)[19]。由于RET基因一般只作用于其靶细胞:即甲状腺C细胞、甲状旁腺细胞和嗜铬细胞,故Sipple综合征的主要表现为MTC(80%~100%)、PHEO(50%)与PHPT(5%~20%)。其中MTC为Sipple综合征的最大的致死病因[19],其发病有年龄轻(平均发病年龄为5~25岁[20])、恶性度高、转移早(颈部淋巴结转移)等特点,若早期未对MTC进行诊疗,5年生存率为80%~90%,10年生存率显著下降至60%~70%,若手术治疗前,MTC已发生转移,患者平均寿命短于40岁。在临床工作中,MTC、PHPT、PHEO的定性诊断、定位诊断对Sipple综合征诊断有十分重要的意义。而原癌基因RET的基因测序更是Sipple综合征的诊断金标准[7]。手术是治疗Sipple综合征的主要措施,但术前需明确有无PHEO的病变。若患者合并PHEO,原则上需优先处理,以避免行其他手术时刺激PHEO释放大量的儿茶酚胺诱发高血压危象。手术推荐保留肾上腺的嗜铬细胞瘤切除术,以避免术后激素分泌不足而引起的肾上腺危象,而作为替代治疗则需长期口服激素药物。目前MTC作为Sipple综合征患者的主要死因,在排除PHEO后,荐行甲状腺全切术+颈部中央淋巴结清扫术,若术中发现甲状旁腺有异常病变,应一并切除。手术时机的选择主要是根据ATA制定的罹患侵袭性MTC的风险来划分[19]:突变位点为P.Arg321Gly等划分为A级,当患者出现以下情况可将手术推迟至5岁后:①每年血清降钙素维持于正常水平;②每年颈部彩超未见明显异常;③少侵袭性的MTC家族史;突变位点为P.Cys630Arg/Phe/Ser/Tyr等划分为B级,突变位点为P.Cys634Arg/Gly/Phe/Ser/Trp/Tyr等划分为C级,均建议5岁内行手术治疗;突变位点为P.Ala 883Phe、P.Met918Thr等划分为D级,建议1岁内或尽早行手术治疗。

[参考文献]

[1] Machens A,Niccoli-Sire P,Hoegel J,et al. Early malignant progression of hereditary medullary thyroid cancer [J]. N Engl J Med,2003,349(16):1517.

[2] 宁志伟,王鸥,裴育,等.RET基因Cys 634 Trp突变致多发性内分泌腺瘤2A型[J].中国医学科学院学报,2006, 28(6):799-802.

[3] 王鸥,邢小平,孟迅吾,等.MEN患者甲状旁腺功能亢进症的临床表现[J].中华内分泌代谢杂志,2004,20(4):296-299.

[4] Romei C,Pardi E,Cetani F,et al. Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2 [J]. J Oncol,2012,2012(6):705036.

[5] Chandrasekharappa SC,Guru SC,Manickam P,et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1 [J]. Science,1997,276(5311):404-407.

[6] Chandrasekharappa SC,Teh BT. Functional studies of the MEN1 gene [J]. J Intern Med,2010,253(6):606-615.

[7] Frankraue K,Buhr H,Dralle H,et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype [J]. Eur J Endocrinol,2006,155(2):229-236.

[8] Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management [J]. Curr Opin Oncol,2005,17(1):7.

[9] Goudet P,Bonithonkopp C,Murat A,et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines [J]. Eur J Endocrinol,2011,165(1):97-105.

[10] Delellis RA. Pathology and genetics of tumours of endocrine organs [M]. Lyon:IARC Press,2004.

[11] Reisch N,Peczkowska M,Januszewicz A,et al. Pheochromocytoma: presentation,diagnosis and treatment [J]. J Hypertens,2006,24(12):2331-2339.

[12] Pinato DJ,Ramachandran R,Toussi STK,et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations [J]. Br J Cancer,2013,108(2):429-437.

[13] González-Escobar A ,Morillo-Sánchez MJ,García-Campos JM. Von Hippel–Lindau disease:Family study [J]. Arch Soc Cir Chile,2012,87(11):368-372.

[14] Schiavi F,Demattè S,Cecchini ME,et al. The endemic paraganglioma syndrome type 1: origin,spread,and clinical expression [J]. J Clin Endocrinol Metab,2012,97(4):E637-E641.

[15] Gattacherifi B,Chabre O,Murat A,et al. Adrenal involvement in MEN1. analysis of 715 cases from the groupe d'etude des tumeurs endocrines database [J]. Eur J Endocrinol,2012,166(2):269-279.

[16] Castellone MD,Verrienti A,Rao DM,et al. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma:functional characterization [J]. Clin Endocrinol,2010,73(4):529-534.

[17] Persu A,Lannoy N,Maiter D,et al. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update [J]. Horm Metab Res,2012,44(5):349.

[18] Amar L,Bertherat J,Baudin E,et al. Genetic testing in pheochromocytoma or functional paraganglioma [J]. J Clin Oncol,2005,23(34):8812-8818.

[19] Brandi ML,Gagel RF,Angeli A,et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2 [J]. J Clin Endocrinol Metab,2001,86(12):5658.

[20] Del PC,Garcíapascual L,Balsells M,et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1. Case report and review of the literature [J]. Hormones,2011, 10(4):326.

(收稿日期:2018-05-21 本文編辑:苏 畅)